Mapping changes in mouse brain metabolism with PET/CT

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 1946-1953

  Welch, Andy ^a   Mingarelli, Marco ^a   Riedel, Gernot ^a   Platt, Bettina ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Brain; Mouse; PET; Preclinical

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACCURACY; AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MAPPING; BRAIN METABOLISM; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FUNCTIONAL NEUROIMAGING; IMAGE ALIGNMENT; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE REGISTRATION; IMAGING AND DISPLAY; INTERMETHOD COMPARISON; LONGITUDINAL STUDY; MALE; MOUSE; NONHUMAN; PARAMETRIC TEST; PERCENTAGE INJECTED DOSE PER GRAM OF TISSUE FOR ABSOLUTE VALUE; PET-CT SCANNER; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RADIOLOGICAL PARAMETERS; REGION OF INTEREST ANALYSIS; SENSITIVITY ANALYSIS; STANDARDIZED UPTAKE VALUE; STATISTICAL PARAMETRIC MAPPING; THREE DIMENSIONAL IMAGING; ANIMAL; BRAIN; METABOLISM; PROCEDURES; RADIOGRAPHY; SCINTISCANNING; TIME; 18F-FDG; METHODOLOGY; PET; PRECLINICAL;

ANIMALS; BRAIN; FEMALE; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

18F-FDG; BRAIN; MOUSE; PET; PRECLINICAL;

EID: 84891702999     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.121509     Document Type: Article

References (43)

1. Meikle SR, Kench P, Kassiou M, Banati RB. Small animal SPECT and its place in the matrix of molecular imaging technologies. Phys Med Biol. 2005;50:R45-R61.
2. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for measurement of local cerebral glucose-utilization: theory, procedure, and normal values in conscious and anesthetized albino-rat. J Neurochem. 1977;28:897-916.
3. Bohnen NI, Djang DSW, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of F-18-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53:59-71.
4. Booij J, Teune LK, Verberne HJ. The role of molecular imaging in the differential diagnosis of parkinsonism. Q J Nucl Med Mol Imaging. 2012;56:17-26.
5. Van Dam D, De Deyn PP. Animal models in the drug discovery pipeline for Alzheimer's disease. Br J Pharmacol. 2011;164:1285-1300.
6. Braidy N, Munoz P, Palacios AG, et al. Recent rodent models for Alzheimer's disease: clinical implications and basic research. J Neural Transm. 2012;119: 173-195.
7. Gilley J, Adalbert R, Coleman MP. Modelling early responses to neurodegenerative mutations in mice. Biochem Soc Trans. 2011;39:933-938.
8. Hall AM, Roberson ED. Mouse models of Alzheimer's disease. Brain Res Bull. 2012;88:3-12.
9. Kitazawa M, Medeiros R, LaFerla FM. Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions. Curr Pharm Des. 2012;18:1131-1147.
10. Toyama H, Ichise M, Liow JS, et al. Absolute quantification of regional cerebral glucose utilization in mice by F-18-FDG small animal PET scanning and 2-C-14-DG autoradiography. J Nucl Med. 2004;45:1398-1405.
11. Mirrione MM, Schiffer WK, Siddiq M, Dewey SL, Tsirka SE. PET imaging of glucose metabolism in a mouse model of temporal lobe epilepsy. Synapse. 2006;59:119-121.
12. Mirrione MM, Schiffer WK, Fowler JS, Alexoff DL, Dewey SL, Tsirka SE. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage. 2007;38:34-42.
13. Day M, Chandran P, Luo F, et al. Latrepirdine increases cerebral glucose utilization in aged mice as measured by [F-18]-fluorodeoxyglucose positron emission tomography. Neuroscience. 2011;189:299-304.
14. Dubois A, Herard A, Delatour B, et al. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage. 2010;51:586-598.
15. Lee JS, Im DS, An Y, Hong JM, Gwag BJ, Joo IS. Chronic cerebral hypoperfusion in a mouse model of Alzheimer's disease: an additional contributing factor of cognitive impairment. Neurosci Lett. 2011;489:84-88.
16. Nicholson RM, Kusne Y, Nowak LA, LaFerla FM, Reiman EM, Valla J. Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res. 2010;1347:179-185.
17. Platt B, Drever B, Koss D, et al. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS ONE. 2011;6:e27068.
18. Platt B, Welch A, Riedel G. FDG-PET imaging, EEG and sleep phenotypes as translational biomarkers for research in Alzheimer's disease. Biochem Soc Trans. 2011;39:874-880.
19. Poisnel G, Herard A, El Tannir El Tayara N, et al. Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging. 2012;33:1995-2005.
20. Reiman EM, Caselli RJ, Alexander GE, Chen KW. Tracking the decline in cerebral glucose metabolism in persons and laboratory animals at genetic risk for Alzheimer's disease. Clin Neurosci Res. 2001;1:194-206.
21. Valla J, Schneider L, Reiman EM. Age-and transgene-related changes in regional cerebral metabolism in PSAPP mice. Brain Res. 2006;1116:194-200.
22. Luo F, Rustay NR, Ebert U, et al. Characterization of 7-and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol Aging. 2012;33:933-944.
23. Kuntner C, Kesner AL, Bauer M, et al. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol. 2009;11:236-240.
24. Friston KJ, Holmes AP, Worsley KJ, Poline J-P, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1995;2:189-210.
25. Ben-Shachar D, Bonne O, Chisin R, et al. Cerebral glucose utilization and platelet mitochondrial complex I activity in schizophrenia: a FDG-PET study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:807-813.
26. Bracco L, Bessi V, Piccini C, Mosconi L, Pupi A, Sorbi S. Metabolic correlates of executive dysfunction: different patterns in mild and very mild Alzheimer's disease. J Neurol. 2007;254:1052-1065.
27. Ito K, Kato T. Positron emission tomography: contribution to diagnosis of dementia and development of disease-modifying drugs. Nihon Shinkei Seishin Yakurigaku Zasshi. 2009;29:153-160.
28. Okamura N, Arai H, Higuchi M, et al. [F-18]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:447-456.
29. XiW, Tian M, Zhang H. Molecular imaging in neuroscience research with smallanimal PET in rodents. Neurosci Res. 2011;70:133-143.
30. Koss D, Drever B, Stoppelkamp S, Riedel G, Platt B. Age-dependent changes in hippocampal synaptic transmission and plasticity in the PLB1-triple Alzheimer mouse. Cell Mol Life Sci. In press.
31. Wang Y, Seidel J, Tsui BMW, Vaquero JJ, Pomper MG. Performance evaluation of the GE Healthcare eXplore VISTA dual-ring small-animal PET scanner. J Nucl Med. 2006;47:1891-1900.
32. Fueger BJ, Czernin J, Hildebrandt I, et al. Impact of animal handling on the results of F-18-FDG PET studies in mice. J Nucl Med. 2006;47:999-1006.
33. Cherry S, Huang S. Effects of scatter on model parameter estimates in 3D PET studies of the human brain. IEEE Trans Nucl Sci. 1995;42:1174-1179.
34. Reimold M, Slifstein M, Heinz A, Mueller-Schauenburg W, Bares R. Effect of spatial smoothing on t-maps: arguments for going back from t-maps to masked contrast images. J Cereb Blood Flow Metab. 2006;26:751-759.
35. Mauchly JW. Significance test for sphericity of a normal n-variate distribution. Ann Math Stat. 1940;11:204-209.
36. Greenhouse SW, Geisser S. On methods in the analysis of profile data. Psychometrika. 1959;24:95-112.
37. Shimoji K, Ravasi L, Schmidt K, et al. Measurement of cerebral glucose metabolic rates in the anesthetized rat by dynamic scanning with 18 F-FDG, the ATLAS small animal PET scanner, and arterial blood sampling. J Nucl Med. 2004;45:665-672.
38. Marx C, Lex B, Calaminus C, et al. Conflict processing in the rat brain: behavioral analysis and functional mPET imaging using [18F] fluorodeoxyglucose. Front Behav Neurosci. 2012;6:1-12.
39. Schulz D, Southekal S, Junnarkar SS, et al. Simultaneous assessment of rodent behavior and neurochemistry using a miniature positron emission tomograph. Nat Methods. 2011;8:347-352.
40. Kyme AZ, Zhou VW, Meikle SR, Baldock C, Fulton RR. Optimised motion tracking for positron emission tomography studies of brain function in awake rats. PLoS ONE. 2011;6:e21727.
41. Poisnel G, Dhilly M, Moustie O, et al. PET imaging with [ 18F]AV-45 in an APP/ PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging. 2012;33:2561-2571.
42. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207-1218.
43. Wu HM, Sui G, Lee C, et al. In vivo quantitation of glucose metabolism in mice using small-animal PET and a microfluidic device. J Nucl Med. 2007;48:837-845.